X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs IPCA LABS - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA IPCA LABS GLENMARK PHARMA/
IPCA LABS
 
P/E (TTM) x 19.4 28.0 69.6% View Chart
P/BV x 3.4 3.6 95.6% View Chart
Dividend Yield % 0.3 0.1 234.1%  

Financials

 GLENMARK PHARMA   IPCA LABS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
IPCA LABS
Mar-18
GLENMARK PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs930695 133.7%   
Low Rs517400 129.4%   
Sales per share (Unadj.) Rs322.6260.2 124.0%  
Earnings per share (Unadj.) Rs28.519.0 150.2%  
Cash flow per share (Unadj.) Rs39.233.1 118.6%  
Dividends per share (Unadj.) Rs2.001.00 200.0%  
Dividend yield (eoy) %0.30.2 151.4%  
Book value per share (Unadj.) Rs183.0213.0 85.9%  
Shares outstanding (eoy) m282.17126.20 223.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.1 106.6%   
Avg P/E ratio x25.428.9 88.0%  
P/CF ratio (eoy) x18.516.6 111.5%  
Price / Book Value ratio x4.02.6 153.8%  
Dividend payout %7.05.3 133.2%   
Avg Mkt Cap Rs m204,20669,120 295.4%   
No. of employees `00013.713.3 103.5%   
Total wages/salary Rs m18,7187,359 254.4%   
Avg. sales/employee Rs Th6,636.82,477.4 267.9%   
Avg. wages/employee Rs Th1,364.7555.2 245.8%   
Avg. net profit/employee Rs Th586.1180.6 324.4%   
INCOME DATA
Net Sales Rs m91,03132,836 277.2%  
Other income Rs m914418 218.7%   
Total revenues Rs m91,94533,254 276.5%   
Gross profit Rs m16,1544,505 358.6%  
Depreciation Rs m3,0191,777 169.9%   
Interest Rs m2,856240 1,188.9%   
Profit before tax Rs m11,1932,905 385.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155511 617.2%   
Profit after tax Rs m8,0392,394 335.8%  
Gross profit margin %17.713.7 129.3%  
Effective tax rate %28.217.6 160.2%   
Net profit margin %8.87.3 121.1%  
BALANCE SHEET DATA
Current assets Rs m69,88719,455 359.2%   
Current liabilities Rs m32,87910,076 326.3%   
Net working cap to sales %40.728.6 142.3%  
Current ratio x2.11.9 110.1%  
Inventory Days Days8198 83.2%  
Debtors Days Days9367 139.7%  
Net fixed assets Rs m28,89220,260 142.6%   
Share capital Rs m282252 111.8%   
"Free" reserves Rs m51,35326,633 192.8%   
Net worth Rs m51,63526,886 192.1%   
Long term debt Rs m41,4182,340 1,769.9%   
Total assets Rs m125,95441,173 305.9%  
Interest coverage x4.913.1 37.6%   
Debt to equity ratio x0.80.1 921.6%  
Sales to assets ratio x0.70.8 90.6%   
Return on assets %8.66.4 135.2%  
Return on equity %15.68.9 174.8%  
Return on capital %15.110.8 140.3%  
Exports to sales %047.6 0.0%   
Imports to sales %014.9 0.0%   
Exports (fob) Rs mNA15,642 0.0%   
Imports (cif) Rs mNA4,884 0.0%   
Fx inflow Rs m36,31715,642 232.2%   
Fx outflow Rs m9,7204,884 199.0%   
Net fx Rs m26,59810,759 247.2%   
CASH FLOW
From Operations Rs m16,4813,411 483.1%  
From Investments Rs m-10,133-1,354 748.4%  
From Financial Activity Rs m-4,685-1,304 359.3%  
Net Cashflow Rs m1,770753 235.0%  

Share Holding

Indian Promoters % 48.3 45.9 105.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 11.4 60.5%  
FIIs % 34.4 25.3 136.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 17.4 60.3%  
Shareholders   56,727 36,892 153.8%  
Pledged promoter(s) holding % 0.0 2.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DISHMAN PHARMA  ELDER PHARMA  VENUS REMEDIES  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Macroeconomic Cues Guide the Markets This Week(Podcast)

Global markets remained in pressure this week. Pound fell sharply as risk of chaotic Brexit rose.

Related Views on News

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Nov 16, 2018 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - SUVEN LIFE COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS